184 GSK Annual Report 2018 Notes to the financial statements continued 30.
Other non-current liabilities 2018 2017 m m Accruals 71 82 Deferred Income 19 22 Other payables 848 877 938 981 Other payables includes acquisition accounting market value lease adjustments and a number of employee-related liabilities.
Net debt 2018 2017 Listing exchange m m Current assets: Liquid investments 84 78 Cash and cash equivalents 3,874 3,833 Cash and cash equivalents reported in Assets held for sale 485 4,443 3,911 Short-term borrowings: Commercial paper 630 529 Bank loans and overdrafts 290 236 Obligations under finance leases 24 23 Drawn bank facility 3,500 5.650% US$ US Medium Term Note 2018 New York Stock Exchange 2,037 0.625% European Medium Term Note 2019 London Stock Exchange 1,349 5,793 2,825 Long-term borrowings: 0.625% European Medium Term Note 2019 London Stock Exchange 1,324 EURIBOR 0.20% European Medium Term Note 2020 London Stock Exchange 677 0.000% European Medium Term Note 2020 London Stock Exchange 1,079 1,060 3.125% US$ US Medium Term Note 2021 New York Stock Exchange 980 LIBOR 0.35% US$ US Medium Term Note 2021 New York Stock Exchange 589 2.850% US$ US Medium Term Note 2022 New York Stock Exchange 1,568 1,474 2.800% US$ US Medium Term Note 2023 New York Stock Exchange 978 919 3.375% US$ US Medium Term Note 2023 New York Stock Exchange 977 1.375% European Medium Term Note 2024 London Stock Exchange 893 876 4.000% European Medium Term Note 2025 London Stock Exchange 670 659 3.625% US$ US Medium Term Note 2025 New York Stock Exchange 780 1.000% European Medium Term Note 2026 London Stock Exchange 629 617 1.250% European Medium Term Note 2026 London Stock Exchange 897 3.375% European Medium Term Note 2027 London Stock Exchange 593 593 3.875% US$ US Medium Term Note 2028 New York Stock Exchange 1,372 1.375% European Medium Term Note 2029 London Stock Exchange 447 439 1.750% European Medium Term Note 2030 London Stock Exchange 673 5.250% European Medium Term Note 2033 London Stock Exchange 982 986 5.375% US$ US Medium Term Note 2034 New York Stock Exchange 390 368 6.375% US$ US Medium Term Note 2038 New York Stock Exchange 2,143 2,021 6.375% European Medium Term Note 2039 London Stock Exchange 694 695 5.250% European Medium Term Note 2042 London Stock Exchange 986 989 4.200% US$ US Medium Term Note 2043 New York Stock Exchange 386 363 4.250% European Medium Term Note 2045 London Stock Exchange 788 789 Obligations under finance leases 44 43 Other long-term borrowings 56 49 20,271 14,264 Net debt 21,621 13,178 185 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 31.
Net debt continued Current assets Liquid investments are classified as financial assets at amortised cost previously available-for-sale investments in prior years.
At 31 December 2018, they included US Treasury Notes and other government bonds.
The effective interest rate on liquid investments at 31 December 2018 was approximately 1.0% 2017 approximately 1.0%.
Liquid investment balances at 31 December 2018 earning interest at floating rates amount to 84 million 2017 78 million.
Liquid investment balances at 31 December 2018 earning interest at fixed rates amount to nil 2017 nil.
The effective interest rate on cash and cash equivalents at 31 December 2018 was approximately 1.9% 2017 approximately 1.3%.
Cash and cash equivalents at 31 December 2018 earning interest at floating and fixed rates amount to 4,094 million and 2 million respectively 2017 3,832 million and 1 million and non-interest bearing holdings amount to 263 million.
GSKs policy regarding the credit quality of cash and cash equivalents is referred to in Note 42, Financial instruments and related disclosures.
Short-term borrowings GSK has a $10 billion 7.9 billion US commercial paper programme, of which $0.8 billion 0.6 billion was in issue at 31 December 2018 2017 $0.7 billion 0.5 billion.
GSK has a 1.9 billion five-year committed facility and $2.5 billion 2.0 billion under a 364 day committed facility.
The five-year committed facility was agreed in September 2015 and extended by one year to 2021 in September 2016.
The 364 day committed facility was agreed in September 2018.
Additional bank facilities were agreed in 2018 to support transactions and two remained active at 31 December 2018.
In June 2018, 3.5 billion was drawn to support the acquisition from Novartis of the remaining stake in the Consumer Healthcare Joint Venture.
In addition, a $5.0 billion bank facility was agreed in December 2018 to support the acquisition of Tesaro and was undrawn at 31 December 2018.
Liquid investments, cash and cash equivalents were as shown in the table on page 184.
The weighted average interest rate on commercial paper borrowings at 31 December 2018 was 2.5% 2017 1.5%.
The weighted average interest rate on current bank loans and overdrafts at 31 December 2018 was 12.0% 2017 4.7%.
At 31 December 2018, short-term loan rates of 60% in Argentina had a disproportionate effect on the weighted average interest rate.
Excluding this impact the weighted average interest rate on current bank loans and overdrafts stands at 4.4%.
The average effective pre-swap interest rate of notes classified as short term at 31 December 2018 was 0.8% 2017 5.9%.
The material decrease in the rate largely reflects the maturity of a 5.65% coupon note in May 2018 and the upcoming maturity of a 0.625% coupon note in December 2019.
Long-term borrowings At the year-end, GSK had long-term borrowings of 20.3 billion 2017 14.3 billion, of which 13.3 billion 2017 10.3 billion falls due in more than five years.
The average effective pre-swap interest rate of all notes in issue at 31 December 2018 was approximately 4.4% 2017 approximately 3.6%.
Long-term borrowings repayable after five years carry interest at effective rates between 1.1% and 6.4%, with repayment dates ranging from 2024 to 2045.
Pledged assets The Group held pledged investments in US Treasury Notes with a par value of $50 million 39 million, 2017 $105 million 78 million as security against irrevocable letters of credit issued on the Groups behalf in respect of the Groups self-insurance activity.
Provisions in respect of self-insurance are included within the provisions for legal and other disputes discussed in Note 29, Other provisions.
In addition, in 2017, 20 million of assets included in Note 22, Other non-current assets, which do not form part of Net debt, were pledged as collateral against future rental payments under operating lease arrangements which were previously entered into by Human Genome Sciences, Inc. prior to its acquisition by the Group, and terminated in 2018.
Finance lease obligations 2018 2017 m m Rental payments due within one year 29 25 Rental payments due between one and two years 20 29 Rental payments due between two and three years 13 9 Rental payments due between three and four years 7 3 Rental payments due between four and five years 4 2 Rental payments due after five years 11 10 Total future rental payments 84 78 Future finance charges 16 12 Total finance lease obligations 68 66
